β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsMechanisms of drug resistance: daptomycin resistanceWhat's new in multidrug-resistant pathogens in the ICU?Targeting of PBP1 by β-lactams determines recA/SOS response activation in heterogeneous MRSA clinical strainsStaphylococcal phenotypes induced by naturally occurring and synthetic membrane-interactive polyphenolic β-lactam resistance modifiersStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibioticsSynergistic activity and mechanism of action of Stephania suberosa Forman extract and ampicillin combination against ampicillin-resistant Staphylococcus aureusDaptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE)Ultrastructural changes in methicillin-resistant Staphylococcus aureus induced by positively charged silver nanoparticlesPenicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin SynergyMulticenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.A current perspective on daptomycin for the clinical microbiologist.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureusAntimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.When sepsis persists: a review of MRSA bacteraemia salvage therapy.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.High-dose daptomycin monotherapy cures Staphylococcus epidermidis 'endotipsitis' after failure of conventional therapy.Acute Angioedema Triggered by DaptomycinModeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs.Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetationsAntimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.In-vitro activity of ceftriaxone combined with newer agents against MRSA.
P2860
Q26752922-1E8DDADE-403D-4DE5-AD45-DAA6CB50D735Q26779944-87664B55-0978-42B5-B745-020BEC88CC55Q28071346-30097EB4-64E4-43F3-95F7-585F4A2E1805Q28486717-4FA4866D-7C42-4513-83E1-38E27073E90FQ28541941-C1380667-B5DB-4A2C-A2F2-00A9580C59C1Q34478074-539D860A-2629-4755-8F55-2910A9A44316Q34648042-47A9C398-5542-403D-9AD4-12ABF4FF3484Q35169018-20A954B8-BB60-410C-97C4-D10357231036Q35179800-107E7AE6-AFB1-4796-BF64-C83A93FF0A90Q35385568-0CD27573-7B92-44C8-9E11-DEB7C876723DQ35596860-73C2A6F3-4031-43E8-86AA-73F4A00685D7Q36073392-1A296154-878B-42ED-BA35-00FFCD5E5D2DQ36389808-62882684-BF1B-4317-9D7F-0F69FDA7A724Q36439093-CD41BB33-1F32-49EA-9A8B-FFADB7EDEB25Q36667027-68F87ED0-6D34-4D0A-B4A0-7CB61D6CE930Q36748977-F7F5D327-DD8C-4D1C-B523-D99BBE8B3964Q37023118-F7EBAD1F-5AFC-428C-89FC-A6953074DA4DQ37263289-E2B84330-B8EA-4575-98ED-37854DFA4B2EQ37287661-E07CB17B-660A-4601-8A83-D17591DF575AQ37538754-70594B7B-42B5-47F4-8B3B-5BEEFF9EA712Q37588890-F06F74EE-280C-416D-B990-7CA4C21D9843Q38286351-1BDA79F1-9C5C-4649-8FE9-4E91B8612226Q38462842-7AB884AF-73C8-41AF-B29F-CB977A72E6E2Q38632488-1F8660FE-CD40-4256-B899-6FEE1B8F9B4CQ39016281-AD6DFB9D-F171-40E9-BC13-53EE1A0DB2F8Q40224839-281C0BD1-5BB1-4B4C-8B96-F58B723267A8Q40320011-0CAA9C91-4061-4FB3-BEE6-CAB4BA571DA7Q40441550-BE8066E3-42A3-45B1-8BBF-DCA46A983B97Q40657995-86D36BFD-44CF-47C7-B2D7-FD9918C0FFD8Q40662901-E4A51E70-4BEE-451C-B008-3D9B4E1BF217Q40709730-79FC3112-2A3C-4ECF-A8F4-9D18ED09456CQ41074267-4A7F9DC1-EC2F-421A-B437-9163CA5FB7FCQ41443468-B24068C4-37EB-4AB9-B138-D410FDFE33F4Q41520373-489DFB94-4CA3-4835-AA11-33EF1BF02DD5Q41883337-5E996EC6-AB7F-41AE-81AD-CD58E31DBB75Q42099202-169B76B4-6888-476E-ACEA-08F917C69123Q42206236-74C145A4-4387-409C-A373-AA79B78DACABQ47318913-3B199851-8421-41C0-A980-CDF8A3296AFFQ47634145-89C9F33E-0791-492B-A5A7-98CB4966DB25Q48281333-9C5FA92A-4836-42B0-9AE2-3C263A6ECE97
P2860
β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@ast
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@en
type
label
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@ast
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@en
prefLabel
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@ast
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@en
P2093
P2860
P356
P1476
β-Lactams increase the antibac ...... tomycin-resistant derivatives.
@en
P2093
Arundhati Paul
Christopher Singh
Konrad B Plata
Roberto R Rosato
Sarah Riosa
Shrenik Mehta
P2860
P304
P356
10.1128/AAC.01525-12
P407
P577
2012-09-17T00:00:00Z